DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
NEW YORK, Jan. 08, 2016 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces that a class action lawsuit has been filed on behalf of purchasers of Vital Therapies, Inc. (NASDAQ:VTL) securities from April 17, 2014 through August 21, 2015 all dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Vital Therapies investors under the federal securities laws.
To join the Vital Therapies class action, go to the website at http://www.rosenlegal.com/cases-671.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period defendants issued materially false and misleading statements to investors and/or failed to disclose material information regarding Vital Therapies’ ELAD System studies, VTI-208, VTI-210, and VTI-212, including: (1) the studies’ independent significance; (2) the degree to which the studies were interrelated; and (3) that in the case of the failure of the VTI-208 trial, Vital Therapies would not continue the VTI-210 trial. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 1, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://www.rosenlegal.com/cases-671.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] www.rosenlegal.com
